Xcovery updates results on x-396

At the time of data cutoff, 41 patients were enrolled with tumor types including NSCLC, head and neck, small cell lung, colorectal and breast cancers. The NSCLC (n=33) patient group included ALK-positive patients (n=23) who were either crizotinib-naïve (n=5) or received prior crizotinib (n=18), as well as ceritinib in two patients.

Among the 17 ALK positive patients evaluable for response (patient completed one cycle and had post baseline response assessment), 10 patients had a partial response (59 percent) and two had stable disease (12 percent).

http://www.xcovery.com/wp-content/uploads/2011/05/Phase-1-Results-of-X-396-in-ALK-positive-NSCLC-at-the-2014-Multidisciplinary-Symposium-in-Thoracic-Oncology-Poster.pdf

This entry was posted in Brain metastases, Lung cancer, Regulatory applications & approvals, Research, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

Leave a Reply